Podcast: Play in new window | Download (Duration: 12:05 — 16.6MB) | Embed
On this episode, I discuss leflunomide pharmacology. It is classified as a DMARD and is primarily used in rheumatoid arthritis.
Leflunomide carries a boxed warning for hepatoxicity. LFTs must be monitored with its use.
Leflunomide can inhibit CYP2C8 which plays an important role in pioglitazone metabolism. Concentrations of pioglitazone can go up on account of this interaction.
TB screening should be done prior to beginning the immunosuppressant leflunomide.
I discuss important drug interactions on the podcast, be sure to check out my latest project which is a 200+ page book on managing drug interactions in primary care.
Be sure to check out our free Top 200 study guide – a 31 page PDF that is yours for FREE!